Abstract A005: 18F-Fluorthanatrace PARP inhibitor PET tracer: Potential implications for theranostics

Clinical Cancer Research · 2025-01-26

Abstract Objective: PARP (poly [ADP-ribose] polymerase) inhibitors are approved for a variety of malignancies including those with a breast, prostate, and ovarian carcinoma, particularly in the setting of a germline or somatic pathogenic BRCA mutation. There is active interest in the development of theranostics including those with a PARP inhibitor backbone. Methods: We evaluate a novel PARP inhibitor (PARPi) PET tracer 18-Fluorine [18F] Fluorthanatrace (FTT). Patients with primary or metastatic solid tumors with measurable disease initiating therapy with a PARP inhibitor monotherapy or in combination with another systemic agent were eligible. Patients underwent 18F-FTT PET/CT prior to initiation of PARPi and a second 18F-FTT PET 2-4 weeks after initiation of a PARP inhibitor. Hematologic toxicity on PARPi monotherapy or combination was assessed using the CTCAEv5.0 criteria. Regions of interest were drawn over the uninvolved bone marrow (usually taken at L3) and normal muscle to obtain the maximum standardized uptake value. Bone marrow to muscle ratio (B/M) was calculated at baseline and on PARPi. Spearman rank correlation coefficient was used. Results: A total of 21 patients were enrolled and underwent 18F-FTT PET. Patients had a median of 0 (range 0-7) prior lines of systemic therapy. The primary disease site included breast (9), ovary (6), primary peritoneal (1), pancreas (1)and other (4). Measurable uptake of 18F-FTT within the tumor and bone marrow was observed in all patients. Median L3 SUVmax at baseline was 4.3 (range 2.1-11.8) vs. 2.33 (range 1.4-2.9) while on PARP inhibitor. Baseline B/M was associated with highest grade hematologic toxicity in patients (n=10) who received talazoparib monotherapy or combination (r=0.65, p=0.042). While B/M was not associated with hematologic toxicity in patients (n=11) who received olaparib monotherapy or combination (r=0.098, p=0.77). Conclusions: 18F-FTT PET can measure target engagement of PARP inhibitors in bone marrow and may have implications for PARP inhibitor-based theranostics and dosing. Results suggest there may be differential impact of different PARPi on bone marrow and should be considered when selecting a backbone for theranostics. Citation Format: Lilie Lin, Mahmoud Hammad, Franklin Wong, Timothy A. Yap. 18F-Fluorthanatrace PARP inhibitor PET tracer: Potential implications for theranostics. [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy; 2025 Jan 26-29; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(2_Suppl):Abstract nr A005.

Longitudinal study on quality of life following cervical cancer treatment in Botswana

BMJ Global Health · 2025-03-01

PURPOSE: This study longitudinally assessed the quality of life (QoL) in patients who completed chemoradiation (CRT) for cervical cancer in Botswana and compared the QoL for those living with and without HIV infection. METHODS: Patients with cervical cancer recommended for curative CRT were enrolled from August 2016 to February 2020. The European Organisation for Research and Treatment of Cancer Core Quality-of-Life (QLQ-C30) and cervical cancer-specific (QLQ-Cx24) questionnaires, translated into Setswana, were used to assess the QoL of patients prior to treatment (baseline), at the end of treatment (EOT) and in 3 month intervals post-treatment for 2 years, and statistical analyses were performed. RESULTS: A total of 294 women (median age: 46 years) were enrolled and followed up for an average of 16.4 months. Of women with recorded staging, most had FIGO stage III/IV disease (64.4%). Women living with HIV (WLWH; 74.1%) presented at earlier ages than those without HIV (44.8 years vs 54.7 years, p<0.001). The QoL for all domains did not differ by HIV status at baseline, EOT or 24 month follow-up. Per QLQ-C30, the mean global health status score (72.21 vs 78.37; p<0.01) and the symptom (12.70 vs 7.63; p=0.04) and functional scales (88.34 vs 91.85; p<0.01) improved significantly from the EOT to the 24 month follow-up for all patients; however, using the QLQ-Cx24 survey, no significant differences in the symptom burden (12.53 vs 13.67; p=0.6) or functional status (91.23 vs 89.90; p=0.53) were found between these two time points. CONCLUSION: The QoL increased significantly for all patients undergoing CRT, underscoring the value of pursuing curative CRT, regardless of the HIV status.

Supplemental Figure S4 from [&lt;sup&gt;18&lt;/sup&gt;F]FluorThanatrace ([&lt;sup&gt;18&lt;/sup&gt;F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

2025-11-25

&lt;p&gt;Baseline [18F]FTT imaging correlates.&lt;/p&gt;

Use of Interactive, Patient-Centric Mobile Health Technology in Sub-Saharan Africa: A Scoping Review

JCO Global Oncology · 2025-08-01 · 1 citations

PURPOSE: Although significant differences in health care outcomes remain between low-middle-income countries and high-income countries, access to mobile devices is comparable. Interactive, patient-centric mobile health (mHealth) technology interventions may mitigate the increasing cancer burden in sub-Saharan Africa. However, these interventions' distribution, efficacy, and feasibility in the region are unknown. METHODS: We compiled literature on two-way, patient-centric mHealth technology in sub-Saharan Africa. We searched online databases for studies completed in sub-Saharan Africa with mHealth interventions (inception to July 23, 2024). Two authors independently completed title/abstract screening. Inclusion criteria were sub-Saharan African setting, age 13 years or older with any health condition, two-way mobile communication, and outcomes studies. Studies that passed title/abstract screening underwent full-text review by two independent authors. Discrepancies were resolved through consensus. Data extraction/review was completed using Covidence software and Microsoft Excel. RESULTS: We retrieved 1,380 unique citations. After screening/review, the final sample size was 37. Randomized controlled trials were most common (n = 20). A plurality took place in Kenya. HIV was the most common condition (n = 30). Interventions included messages about medication/appointment adherence and patient status. Most studies (32 of 37 [86%]) had at least one positive finding. Study characteristics varied widely for those with positive findings, but using various message frequencies, or peer navigators/social supporters increased success. All studies with no positive findings were randomized controlled trials; four of the five were on HIV. CONCLUSION: Most two-way, patient-centric mHealth interventions in sub-Saharan Africa have been successful by at least one measure. Interventions have primarily been for patients with HIV. No studies have focused on cancer. With the increasing cancer burden in sub-Saharan Africa, an understanding of mHealth in oncologic settings is greatly needed.

Data from Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation

2025-02-17

&lt;div&gt;AbstractPurpose:&lt;p&gt;Human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response.&lt;/p&gt;Experimental Design:&lt;p&gt;A total of 66 patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma was collected at baseline, weeks 1, 3, and 5 of chemoRT, and 3 to 4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy.&lt;/p&gt;Results:&lt;p&gt;The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared with those who received standard-of-care therapy. HPV cfDNA clearance correlated with better 2-year RFS (92.9% vs. 30%, log-rank; &lt;i&gt;P&lt;/i&gt; = 0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index score of 0.83, which improved when combined with MRI response (concordance index, 0.88).&lt;/p&gt;Conclusions:&lt;p&gt;HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at follow-up predict RFS, and delivery of therapeutic HPV vaccine with chemoRT was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.&lt;/p&gt;&lt;/div&gt;

Management of De-Novo Stage IVB Cervical Cancer with Induction Chemotherapy Followed by Definitive Chemoradiation

International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

Supplemental Figure S5 from [&lt;sup&gt;18&lt;/sup&gt;F]FluorThanatrace ([&lt;sup&gt;18&lt;/sup&gt;F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

2025-11-25

&lt;p&gt;Clinical response correlates.&lt;/p&gt;

Supplemental Figure S6 from [&lt;sup&gt;18&lt;/sup&gt;F]FluorThanatrace ([&lt;sup&gt;18&lt;/sup&gt;F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

2025-11-25

&lt;p&gt;18F]FTT-PET on subject previously treated with PARPi.&lt;/p&gt;

Supplementary Materials 1 from Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation

2025-02-17

&lt;p&gt;Supplementary Figures and Tables&lt;/p&gt;

Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S

Gynecologic Oncology · 2025-09-01 · 5 citations